Artesunate Amivas is an antimalarial indicated for the initial treatment of severe malaria in adults and children.
For information regarding Artesunate for Injection, including the approved Prescribing Information (for Healthcare Providers only), please click on the links below.
- EMA Product Information
- Annex I – Summary of Product Characteristics
- Annex IIA – Manufacturing-authorisation holder responsible for batch release
- Annex IIB – Conditions of the marketing authorisation
- Annex IIIA – Labelling
- Annex IIIB – Package Leaflet
This information may also be downloaded from the EMA website in EU/EEA national languages. Go to https://www.ema.europa.eu/en/medicines and click category human – with the search term Artesunate Amivas.
- MHRA Product Information
- Summary of Product Characteristics
- Product Information Leaflet
This information may also be downloaded from the MHRA website (English only). Go to https://products.mhra.gov.uk and use the search term Artesunate Amivas.
To order Artesunate Amivas:
Artesunate Amivas is currently not available for the EU/EEA/UK markets but we are working diligently to make it available soon.
If you require further information or have questions, there are a number of options available. Please send us an email at firstname.lastname@example.org or call us on our Medical Affairs information numbers or make an inquiry through our contact page.
Healthcare professionals with product related questions should the Amivas Medical Affairs line below:
AMIVAS MEDICAL AFFAIRS
REGISTERING ARTESUNATE FOR INJECTION USED DURING PREGNANCY
Please register treatments of pregnant women using this register:
Pregnancy register link is coming.
RETURN OF GOODS POLICY
Important Safety Information
Important Safety Information
Hypersensitivity to the active substance, to any other artemisinin antimalarial agent or to any of the excipients listed in section 6.1 of the SmPC.
Special Warnings and Precautions for Use
Allergic reactions to intravenous artesunate, including anaphylaxis have been reported. Other reported allergic reactions include urticaria, rash and pruritus.
Post Artesunate Delayed Haemolysis:
Post-artesunate delayed haemolysis (PADH) is characterised by decreased haemoglobin with laboratory evidence of haemolysis (such as decreased haptoglobin and increased lactate dehydrogenase) with onset at least 7 days and sometimes several weeks after initiating artesunate treatment. PADH has been reported to occur very commonly after successful treatment of severe malaria that commenced with IV artesunate in returning travellers. The risk of PADH may be highest in patients with hyperparasitaemia and in younger children. Patients should be monitored for evidence of haemolytic anaemia for 4 weeks after starting artesunate treatment. Spontaneous recovery from PADH usually occurs within a few weeks. Some patients require transfusion.
The artemisinins have shown direct inhibitory effects on human erythroid precursors in vitro and inhibit bone marrow responses (especially red blood cell precursors) in animal models. Both animal preclinical data and human data from clinical trials have suggested that reversible reticulocytopenia occurs at least commonly in association with treatment with intravenous artesunate. The reticulocyte count recovers after cessation of treatment.
Malaria due to Plasmodium vivax, Plasmodium malariae or Plasmodium ovale
Artesunate Amivas has not been evaluated in the treatment of severe malaria due to Plasmodium vivax, Plasmodium malariae or Plasmodium ovale. Available data indicates that it is effective against all Plasmodium species (see section 5.1 of the SmPC). It does not treat the hypnozoite liver stage forms of Plasmodium and will therefore not prevent relapses of malaria due to Plasmodium vivax or Plasmodium ovale. Patients treated initially with artesunate for severe malaria due to P. vivax or P. ovale should receive an antimalarial agent that is active against the hypnozoite liver stage forms of Plasmodium.
Infants aged less than 6 months
There are insufficient clinical data to establish the safety and efficacy of Artesunate Amivas in infants below 6 months of age. Pharmacokinetic modelling and simulations indicate that after 2.4 mg/kg IV artesunate the dihydroartemisinin (DHA) plasma exposures in infants aged less than 6 months are likely to be higher than those in older infants and children.
There are insufficient clinical data to establish the safety and efficacy of intravenous artesunate in patients aged 65 years and older with severe malaria.
Information about excipients
This medicinal product contains 193 mg sodium per the recommended single dose for a 60 kg adult, equivalent to 9.6 % of the WHO recommended maximum daily intake of 2 g sodium for an adult. As the first and second doses are recommended 12 hours apart, on days when two doses are given in a 24-hour period, then the dose would be 386 mg sodium per day, equivalent to 19.2 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Summary of the Safety Profile:
The most common adverse drug reaction reported in clinical trials has been anaemia. While anaemia occurs very commonly in patients with severe malaria as a result of the disease and effective treatment, anaemia that was not dose-related was also reported in healthy subjects in clinical pharmacology studies with IV artesunate. Post‑Artesunate Delayed Haemolysis (PADH) has been reported very commonly following effective treatment of severe malaria with IV artesunate in travellers and in children. Reticulocytopaenia that resolves after completion of treatment with IV artesunate occurs commonly or very commonly.
No clinical drug-drug interactions studies have been conducted with Artesunate Amivas.
Effect of other medicinal products on artesunate and/or dihydroartemisinin (DHA)
After intravenous administration, artesunate is converted to DHA by esterases and by CYP2A6. DHA is converted to inactive glucuronide conjugates primarily by UGT1A9. Co-administration of intravenous artesunate with strong inhibitors of UGT enzymes (e.g., axitinib, vandetanib, imatinib, diclofenac) may increase plasma exposures to DHA. Co-administration should be avoided if possible. Co-administration of Artesunate Amivas with UGT inducers (e.g., nevirapine, ritonavir, rifampicin, carbamazepine, phenytoin) may decrease DHA exposures, leading to a reduction in, or loss of, efficacy. Co-administration should be avoided.
Effect of artesunate and/or DHA on other medicinal products
Limited data from in-vitro studies and from clinical drug-drug interaction studies with oral artesunate and/or oral DHA have indicated that DHA induces CYP3A and inhibits CYP1A2. Caution is advised when co-administering intravenous artesunate with substrates of CYP3A4 or CYP1A2 that have narrow therapeutic windows.
Use in Specific Populations
Pregnancy: There is limited clinical experience with the use of Artesunate Amivas in the first trimester of pregnancy. A risk to the foetus cannot be excluded. Animal studies have shown reproductive toxicity. The use of Artesunate Amivas in the first trimester is therefore not recommended unless the benefit to the mother outweighs the risk to the foetus.
A moderate amount of clinical data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of artesunate when given IV in their second or third trimester. As a precautionary measure, it is preferable to avoid the use of Artesunate Amivas during the second or third trimester of pregnancy.
A pregnancy registry has been set up to monitor all pregnancies and their outcomes following treatment with Artesunate Amivas.
Pediatric Use: Refer to Special Warnings and Precautions for Use
Geriatric Use: Refer to Special Warnings and Precautions for Use
To report SUSPECTED ADVERSE REACTIONS, contact Amivas Ireland at MICC.Amivas@4cpharma.com
- Spain: 900 997 936
- Switzerland: 0800 564 848
- Germany: 0800 4007347
- France: 0 800 91 38 08
- UK: 0800 014 8494
- Italy: 800 697 941
The YellowCard may also be filed in the UK. https://yellowcard.mhra.gov.uk